We know that OI is only one tool in the box. But it is under-used in this sector, and that means opportunities are being missed. That’s why we actively support multiple ways to use OI, and tenants get involved if and when it suits them.
Open Innovation (OI) was originally defined by UC Berkeley academic Henry Chesbrough as ‘any external collaboration’. He was studying companies suffering from what we now call ‘Not Invented Here Syndrome’, a workplace culture that acts as a barrier to realising the value of new opportunities or ways of working.
The rise of OI has brought us more of the familiar forms of collaboration, such as industry-funded PhDs, and a whole raft of new methods of collaboration that would never have been considered just a few years ago. These include open innovation challenges, multi-pharma consortia that share pre-competitive information, open data initiatives – and SBC, the UK’s first biomedical open innovation campus.
Whatever method of OI you’re using, it’s the usual rules of collaboration. You share what you want, and you keep the rest. You use non-disclosure and IP agreements as you wish. Tenants at SBC have no obligation whatsoever to reveal information or collaborate with GSK or anyone else. It’s their choice.
How do we do it? Take a look at our OI activities.
Prof Richard Knowles